You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

woman drinking from a bottle
Relvar Ellipta

Relvar Ellipta is an easy to use device with three simple steps1 that is both preferred by patients, and leads to fewer critical errors, vs other asthma devices2

Ellipta device and instructions Ellipta device and instructions

How to use Relvar Ellipta

How does Relvar Ellipta compare with other devices?

Ellipta device vs. other devices Ellipta device vs. other devices

Ellipta is preferred by patients vs Turbohaler, Diskus and MDI, with fewer patients making critical errors vs Turbohaler.2

patient critical error graph patient critical error graph

This graph has been independently created by GSK from the original data. The same results were first published in van der Palen J, et al. NJP Prim Care Respir Med 2016; 26:16079.
MDI and Diskus did not meet statistical significance.
Critical error defined as errors that are likely to result in no or minimal medication being inhaled.2

Discover Relvar

woman staring

Defining asthma control

How do patient perceptions of asthma control differ from guideline definitions?

FIND OUT MORE
Woman staring out of window

Proactive asthma control

See how Relvar can help achieve asthma control

FIND OUT MORE
woman stretching

Safety

Read about the safety profile associated with Relvar

FIND OUT MORE
woman drinking from a bottle

Molecular properties

Uncover the unique molecular profile of Relvar

FIND OUT MORE

Need help with this product?

Request a contact

From a sales representatives

Stay informed

Get the latest updates from GSK

Abbreviations

MDI, metered dose inhaler.

References
  1. Global Datasheet Fluticasone furoate/vilanterol: v11, March 2020.
  2. van der Palen J, et al. NJP Prim Care Respir Med 2016;26:16079.
  3. Svedsater H, et al. NPJ Prim Care Respir Med 2014;24:14019.

RELVAR Ellipta was created in collaboration with

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

PM-IE-FFV-WCNT-230009 June 2023